P01-114

A RANDOMIZED AND DOUBLE- BLIND CLINICAL TRIAL OF VENLAFAXINE HYDROCHLORIDE SUSTAINED RELEASE CAPSULES FOR TREATING JUVENILE DEPRESSION

C. Hongfen[1], J. Weidong[1], Z. Guoquan[1], Y. Chuang[2], G. Tianyou[3]

[1]Psychiatry, Shanghai Changning Mental Health Center/Bio-X Center Hospital of Shanghai Jiaotong University, Shanghai, [2]Psychiatry, Wenzhou Medical Collage, Wenzhou, [3]Psychology, Shenzhen University, Shenzhen, China

Object: To evaluate the efficacy and safety of venlafaxine hydrochloride(HCL) sustained release capsules in treating juvenile with depressive disorder.

Methods: A randomized, double blind dummy clinical trial enrolled 60 adolescent patients with depression, who were randomizedly designed to administer venlafaxine HCL sustained release capsules 150 mg or fluoxetine 20 mg daily for 8 weeks. The efficacies of both treatment groups was evaluated based on the Hamilton Depression Scale and Clinical General impression Scale pre and post-treatment.

Results: The scores of Hamilton Depression Scale at the end of therapy were significantly reduced compared with the baseline in both gtnups (P< 0.O1). The effective rate of venlafaxine HCL sustained release capsules versus fluoxetine treatmlent was 70.0% and 65.5%, respectively, the P value showed no statistical difference (P>0. OS). The common adverse reactions included dry mouth, insomnia, dizziness, and loss of appetite.

Conclusion: Venlafaxine HCl sustained release capsules is an effective agent for juvenile with major depression.

https://doi.org/10.1016/S0924-9338(09)70735-7 Published online by Cambridge University Press